Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022
在SARS-CoV-2 Omicron BA.1和BA.2/BA.2.12.1亚系占主导地位的时期，免疫功能正常的成年人接种2剂、3剂和4剂COVID-19 mRNA疫苗的有效性——VISION网络，10个州，2021年12月至2022年6月
期刊:Mmwr-Morbidity and Mortality Weekly Report
影响因子:17.3
doi:10.15585/mmwr.mm7129e1
Link-Gelles, Ruth; Levy, Matthew E; Gaglani, Manjusha; Irving, Stephanie A; Stockwell, Melissa; Dascomb, Kristin; DeSilva, Malini B; Reese, Sarah E; Liao, I-Chia; Ong, Toan C; Grannis, Shaun J; McEvoy, Charlene; Patel, Palak; Klein, Nicola P; Hartmann, Emily; Stenehjem, Edward; Natarajan, Karthik; Naleway, Allison L; Murthy, Kempapura; Rao, Suchitra; Dixon, Brian E; Kharbanda, Anupam B; Akinseye, Akintunde; Dickerson, Monica; Lewis, Ned; Grisel, Nancy; Han, Jungmi; Barron, Michelle A; Fadel, William F; Dunne, Margaret M; Goddard, Kristin; Arndorfer, Julie; Konatham, Deepika; Valvi, Nimish R; Currey, J C; Fireman, Bruce; Raiyani, Chandni; Zerbo, Ousseny; Sloan-Aagard, Chantel; Ball, Sarah W; Thompson, Mark G; Tenforde, Mark W
